SRR1421198
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.411
- KRAS_SIGNALING_DN+0.337
- SPERMATOGENESIS+0.247
- BILE_ACID_METABOLISM+0.234
- APICAL_SURFACE+0.215
- ALLOGRAFT_REJECTION+0.193
- MYOGENESIS+0.156
- KRAS_SIGNALING_UP+0.147
- INFLAMMATORY_RESPONSE+0.123
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.102
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.639
- MYC_TARGETS_V2-0.580
- MYC_TARGETS_V1-0.571
- UNFOLDED_PROTEIN_RESPONSE-0.530
- DNA_REPAIR-0.521
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- MTORC1_SIGNALING-0.476
- PROTEIN_SECRETION-0.468
- ADIPOGENESIS-0.440
- PI3K_AKT_MTOR_SIGNALING-0.439
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1349829 | GTEX | — | 0.959 |
| 2 | SRR1353285 | GTEX | — | 0.950 |
| 3 | SRR1413454 | GTEX | — | 0.949 |
| 4 | SRR1474886 | GTEX | — | 0.947 |
| 5 | SRR1339549 | GTEX | — | 0.944 |
| 6 | SRR1468974 | GTEX | — | 0.944 |
| 7 | MNG436 | — | — | 0.942 |
| 8 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.940 |
| 9 | SRR1348861 | GTEX | — | 0.939 |
| 10 | SRR1337431 | GTEX | — | 0.939 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.411 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.337 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.247 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.234 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.215 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.193 | Idelalisib | — uncovered |
| MYOGENESIS | 0.156 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.147 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.123 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.102 | Inavolisib | — uncovered |
| COAGULATION | 0.068 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.042 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.002 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.002 | Idelalisib | — uncovered |